过去，治疗失眠要么依赖药物，要么求助于为数不多的专业心理治疗师。如今，一类新事物正悄然改变格局——数字疗法（Digital Therapeutics，简称 DTx）。它以软件为载体，把经过临床验证的治疗方法装进手机，让原本稀缺的专业干预得以规模化触达。在睡眠领域，DTx 正被视为下一个值得关注的风口。
什么是数字疗法
数字疗法并非普通的健康类 App，它的核心在于「循证」与「干预」：基于有临床证据的治疗方案，通过软件对特定疾病进行预防、管理或治疗，并以真实疗效为目标。在失眠领域，最成熟的应用就是把「失眠认知行为治疗（CBT-I）」数字化——这一被国际指南列为一线的非药物疗法，过去受限于治疗师数量难以普及，而 DTx 恰好补上了这块短板。
为什么切入口是睡眠
失眠之所以成为 DTx 的理想切入口，有几重原因：其一，需求庞大且长期，慢性失眠人群基数大；其二，CBT-I 有扎实的循证基础，方法可标准化、可拆解为模块，天然适合软件化；其三，相比药物，数字方案没有依赖与宿醉风险，更适合长期、规模化使用。当「成熟的疗法」遇上「稀缺的供给」，数字化便有了用武之地。
机会与商业化路径
DTx 的商业空间正在打开：面向个人用户的订阅制产品、与医院和睡眠中心合作的处方式服务、纳入企业健康管理或商业保险的支付方……不同路径对应不同的获客与变现逻辑。对从业者而言，关键不在于把内容做得花哨，而在于能否证明「真有效」——疗效数据，才是 DTx 区别于普通助眠 App 的护城河。
门槛与隐忧
风口之下，挑战同样真实。首先是循证门槛：真正的 DTx 需要临床试验支撑，研发周期长、成本高；其次是依从性，再好的方案，用户半途而废也无从谈效果，如何用产品设计提升坚持率是核心课题；此外，监管与支付体系尚在完善，数据隐私也必须妥善处理。把「医疗的严谨」与「产品的体验」结合好，才是这条路走通的前提。
趋势观察
可以预见，睡眠 DTx 会朝几个方向演进：与可穿戴监测打通，形成「评估—干预—反馈」的闭环；引入人工智能实现更个性化的方案调整；从单一失眠扩展到与焦虑、慢病共病的综合管理。它未必会取代药物与面诊，但很可能成为睡眠健康服务体系中越来越重要的一环。
理性看待：别神化，也别低估
面对 DTx 的热度，从业者与用户都需要一份平常心。一方面，不应把它神化为「一键治愈失眠」的灵丹妙药——它本质上是把行之有效的方法做得更可及，仍离不开用户的配合与坚持；另一方面，也不必因市场上鱼龙混杂而全盘否定，真正经过验证的数字疗法，确实能为许多人提供低门槛、可负担的帮助。对监管者而言，建立清晰的准入与评价标准、区分「真疗法」与「伪概念」，是行业健康发展的前提。
深度观察：数字疗法的想象力，在于让「有效的治疗」突破人力与地域的限制。但它的天花板与底线，最终都取决于两个字——疗效。能用证据说话的产品，才配得上「疗法」之名。
In the past, treating insomnia meant either relying on medication or turning to the relatively few professional psychotherapists. Now, a new kind of solution is quietly changing the landscape—digital therapeutics (DTx). Using software as the carrier, it packs clinically validated treatment methods into a phone, allowing once-scarce professional intervention to reach people at scale. In the sleep field, DTx is being seen as the next trend worth watching.
What Are Digital Therapeutics?
Digital therapeutics are not ordinary health apps; their core lies in being "evidence-based" and "interventional": based on treatment plans backed by clinical evidence, they use software to prevent, manage, or treat specific diseases, with real efficacy as the goal. In the insomnia field, the most mature application is digitizing "cognitive behavioral therapy for insomnia (CBT-I)"—a non-drug therapy listed as first-line by international guidelines, which in the past was hard to popularize due to the limited number of therapists, and DTx fills exactly this gap.
Why Sleep Is the Entry Point
There are several reasons insomnia has become an ideal entry point for DTx: first, the demand is large and long-term, with a huge population of chronic insomnia sufferers; second, CBT-I has a solid evidence base, and its methods can be standardized and broken down into modules, making it naturally suited to being turned into software; third, compared with medication, digital solutions carry no risk of dependence or hangover, making them more suitable for long-term, large-scale use. When a "mature therapy" meets a "scarce supply," digitization has its place to shine.
Opportunities and Commercialization Paths
The commercial space for DTx is opening up: subscription products aimed at individual users, prescription-based services in partnership with hospitals and sleep centers, and payment models incorporated into corporate health management or commercial insurance—different paths correspond to different logics of customer acquisition and monetization. For practitioners, the key lies not in making the content flashy but in whether they can prove it "really works"—efficacy data is the moat that distinguishes DTx from ordinary sleep-aid apps.
Barriers and Concerns
Beneath the trend, the challenges are equally real. First is the evidence barrier: genuine DTx requires the support of clinical trials, with a long development cycle and high cost. Second is adherence: no matter how good the plan, if users give up halfway there is no efficacy to speak of, so how to use product design to improve persistence is a core issue. In addition, the regulatory and payment systems are still being refined, and data privacy must be handled properly. Combining "medical rigor" with "product experience" is the prerequisite for this path to succeed.
Trend Observation
It is foreseeable that sleep DTx will evolve in several directions: connecting with wearable monitoring to form an "assessment—intervention—feedback" loop; introducing artificial intelligence to achieve more personalized plan adjustments; and expanding from insomnia alone to integrated management of comorbidities such as anxiety and chronic disease. It may not necessarily replace medication and in-person consultation, but it is very likely to become an increasingly important part of the sleep health service system.
View It Rationally: Neither Deify Nor Underestimate
In the face of the DTx hype, both practitioners and users need a measure of composure. On the one hand, it should not be deified as a "one-click cure for insomnia" panacea—in essence, it makes proven effective methods more accessible, but still cannot do without users' cooperation and persistence; on the other hand, there is no need to dismiss it wholesale because of the mixed quality on the market, as genuinely validated digital therapeutics can indeed provide many people with low-barrier, affordable help. For regulators, establishing clear access and evaluation standards and distinguishing "true therapies" from "false concepts" is the prerequisite for healthy industry development.
In-depth observation: The imagination of digital therapeutics lies in letting "effective treatment" break through the limits of manpower and geography. But its ceiling and its bottom line ultimately come down to one thing—efficacy. Only products that can let the evidence speak deserve the name "therapy."